N
NEKTAR THERAPEUTICS
NASDAQ: NKTR (Nektar Therapeutics)
Last update: 1 hour ago70.59
-0.08 (-0.11%)
| Previous Close | 70.67 |
| Open | 70.72 |
| Volume | 603,094 |
| Avg. Volume (3M) | 1,003,803 |
| Market Cap | 2,384,955,904 |
| Price / Earnings (Forward) | 34.01 |
| Price / Sales | 24.82 |
| Price / Book | 4.14 |
| 52 Weeks Range | |
| Earnings Date | 13 Aug 2026 |
| Profit Margin | -152.49% |
| Operating Margin (TTM) | -424.15% |
| Diluted EPS (TTM) | -9.45 |
| Quarterly Revenue Growth (YOY) | -51.70% |
| Total Debt/Equity (MRQ) | 1,358.71% |
| Current Ratio (MRQ) | 3.24 |
| Operating Cash Flow (TTM) | -176.87 M |
| Levered Free Cash Flow (TTM) | -47.84 M |
| Return on Assets (TTM) | -26.80% |
| Return on Equity (TTM) | -189.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Nektar Therapeutics | Mixed | Bullish |
AIStockmoo Score
1.5
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.50 |
|
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.29% |
| % Held by Institutions | 67.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Two Seas Capital Lp | 31 Mar 2026 | 1,959,178 |
| Armistice Capital, Llc | 31 Mar 2026 | 578,000 |
| Sofinnova Investments, Inc. | 31 Mar 2026 | 509,546 |
| Woodline Partners Lp | 31 Mar 2026 | 415,335 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |